Wire · opportunities
FDA approves Isembyld, first treatment to target muscle in spinal muscular atrophy
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 September 2026 · Fusion42 review
The FDA approved Isembyld, the first treatment targeting muscle in spinal muscular atrophy (SMA) for patients aged 2 and older, demonstrating motor function improvement in combination with existing SMN2-targeted therapies.
This Wire brief sits within Fusion42's coverage of Biotech, and 11 sources have reported it between 12 Sep 2026 and 25 Sep 2026.
◆ ◆ The Wire takeaway
You face a newly opened route to market in SMA treatments by combining muscle-targeting therapies with existing neuron-focused drugs. This approval signals that additive or complementary therapies will gain traction quickly in rare neuromuscular diseases.
◆ Coverage
11 sources · first reported 12 Sep 2026 · latest 25 Sep 2026
◆ Topics